Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Gene silencing with CRISPRi in bacteria and optimization of dCas9 expression levels.

Depardieu F, Bikard D.

Methods. 2019 Aug 1. pii: S1046-2023(18)30497-3. doi: 10.1016/j.ymeth.2019.07.024. [Epub ahead of print]

PMID:
31377338
2.

Genome-wide CRISPR-dCas9 screens in E. coli identify essential genes and phage host factors.

Rousset F, Cui L, Siouve E, Becavin C, Depardieu F, Bikard D.

PLoS Genet. 2018 Nov 7;14(11):e1007749. doi: 10.1371/journal.pgen.1007749. eCollection 2018 Nov.

3.

PhageTerm: a tool for fast and accurate determination of phage termini and packaging mechanism using next-generation sequencing data.

Garneau JR, Depardieu F, Fortier LC, Bikard D, Monot M.

Sci Rep. 2017 Aug 15;7(1):8292. doi: 10.1038/s41598-017-07910-5.

4.

A Eukaryotic-like Serine/Threonine Kinase Protects Staphylococci against Phages.

Depardieu F, Didier JP, Bernheim A, Sherlock A, Molina H, Duclos B, Bikard D.

Cell Host Microbe. 2016 Oct 12;20(4):471-481. doi: 10.1016/j.chom.2016.08.010. Epub 2016 Sep 22.

5.

Competition between VanU(G) repressor and VanR(G) activator leads to rheostatic control of vanG vancomycin resistance operon expression.

Depardieu F, Mejean V, Courvalin P.

PLoS Genet. 2015 Apr 21;11(4):e1005170. doi: 10.1371/journal.pgen.1005170. eCollection 2015 Apr.

6.

D-Ala-d-Ser VanN-type transferable vancomycin resistance in Enterococcus faecium.

Lebreton F, Depardieu F, Bourdon N, Fines-Guyon M, Berger P, Camiade S, Leclercq R, Courvalin P, Cattoir V.

Antimicrob Agents Chemother. 2011 Oct;55(10):4606-12. doi: 10.1128/AAC.00714-11. Epub 2011 Aug 1.

7.

Inducible expression eliminates the fitness cost of vancomycin resistance in enterococci.

Foucault ML, Depardieu F, Courvalin P, Grillot-Courvalin C.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16964-9. doi: 10.1073/pnas.1006855107. Epub 2010 Sep 10.

8.

VanB-type Enterococcus faecium clinical isolate successively inducibly resistant to, dependent on, and constitutively resistant to vancomycin.

San Millan A, Depardieu F, Godreuil S, Courvalin P.

Antimicrob Agents Chemother. 2009 May;53(5):1974-82. doi: 10.1128/AAC.00034-09. Epub 2009 Mar 9.

9.

New combinations of mutations in VanD-Type vancomycin-resistant Enterococcus faecium, Enterococcus faecalis, and Enterococcus avium strains.

Depardieu F, Foucault ML, Bell J, Dubouix A, Guibert M, Lavigne JP, Levast M, Courvalin P.

Antimicrob Agents Chemother. 2009 May;53(5):1952-63. doi: 10.1128/AAC.01348-08. Epub 2009 Mar 2.

10.

Modes and modulations of antibiotic resistance gene expression.

Depardieu F, Podglajen I, Leclercq R, Collatz E, Courvalin P.

Clin Microbiol Rev. 2007 Jan;20(1):79-114. Review.

11.
12.
13.

VanD-type vancomycin-resistant Enterococcus faecium and Enterococcus faecalis.

Depardieu F, Kolbert M, Pruul H, Bell J, Courvalin P.

Antimicrob Agents Chemother. 2004 Oct;48(10):3892-904.

14.

Expression of glycopeptide-resistance gene in response to vancomycin and teicoplanin in the cardiac vegetations of rabbits infected with VanB-type Enterococcus faecalis.

Lefort A, Arthur M, Depardieu F, Chau F, Pouzet C, Courvalin P, Fantin B.

J Infect Dis. 2004 Jan 1;189(1):90-7. Epub 2003 Dec 22.

PMID:
14702158
16.

The vanG glycopeptide resistance operon from Enterococcus faecalis revisited.

Depardieu F, Bonora MG, Reynolds PE, Courvalin P.

Mol Microbiol. 2003 Nov;50(3):931-48.

17.

Influence of VanD type resistance on activities of glycopeptides in vitro and in experimental endocarditis due to Enterococcus faecium.

Lefort A, Garry L, Depardieu F, Courvalin P, Fantin B.

Antimicrob Agents Chemother. 2003 Nov;47(11):3515-8.

18.

VanD-type vancomycin-resistant Enterococcus faecium 10/96A.

Depardieu F, Reynolds PE, Courvalin P.

Antimicrob Agents Chemother. 2003 Jan;47(1):7-18. Review.

19.
20.

Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America.

Tait-Kamradt A, Davies T, Appelbaum PC, Depardieu F, Courvalin P, Petitpas J, Wondrack L, Walker A, Jacobs MR, Sutcliffe J.

Antimicrob Agents Chemother. 2000 Dec;44(12):3395-401.

21.
22.

Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.

Arthur M, Depardieu F, Reynolds P, Courvalin P.

Antimicrob Agents Chemother. 1999 Aug;43(8):1875-80.

23.

Single-cell analysis of glycopeptide resistance gene expression in teicoplanin-resistant mutants of a VanB-type Enterococcus faecalis.

Baptista M, Rodrigues P, Depardieu F, Courvalin P, Arthur M.

Mol Microbiol. 1999 Apr;32(1):17-28.

24.

Requirement of the VanY and VanX D,D-peptidases for glycopeptide resistance in enterococci.

Arthur M, Depardieu F, CabaniƩ L, Reynolds P, Courvalin P.

Mol Microbiol. 1998 Nov;30(4):819-30.

25.

Two-step acquisition of resistance to the teicoplanin-gentamicin combination by VanB-type Enterococcus faecalis in vitro and in experimental endocarditis.

Lefort A, Baptista M, Fantin B, Depardieu F, Arthur M, Carbon C, Courvalin P.

Antimicrob Agents Chemother. 1999 Mar;43(3):476-82.

26.

Oxygen tolerance in patients with acute respiratory failure.

Capellier G, Beuret P, Clement G, Depardieu F, Ract C, Regnard J, Robert D, Barale F.

Intensive Care Med. 1998 May;24(5):422-8.

PMID:
9660255
27.

Mutations leading to increased levels of resistance to glycopeptide antibiotics in VanB-type enterococci.

Baptista M, Depardieu F, Reynolds P, Courvalin P, Arthur M.

Mol Microbiol. 1997 Jul;25(1):93-105.

28.

Selection of glycopeptide-resistant mutants of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis.

Aslangul E, Baptista M, Fantin B, Depardieu F, Arthur M, Courvalin P, Carbon C.

J Infect Dis. 1997 Mar;175(3):598-605.

PMID:
9041331
29.
30.

Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis.

Baptista M, Depardieu F, Courvalin P, Arthur M.

Antimicrob Agents Chemother. 1996 Oct;40(10):2291-5.

31.

Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci.

Arthur M, Depardieu F, Reynolds P, Courvalin P.

Mol Microbiol. 1996 Jul;21(1):33-44.

PMID:
8843432
32.

Mechanisms of glycopeptide resistance in enterococci.

Arthur M, Reynolds PE, Depardieu F, Evers S, Dutka-Malen S, Quintiliani R Jr, Courvalin P.

J Infect. 1996 Jan;32(1):11-6. Review.

PMID:
8852545
33.

The vanZ gene of Tn1546 from Enterococcus faecium BM4147 confers resistance to teicoplanin.

Arthur M, Depardieu F, Molinas C, Reynolds P, Courvalin P.

Gene. 1995 Feb 27;154(1):87-92.

PMID:
7867956
34.

Glycopeptide resistance mediated by enterococcal transposon Tn1546 requires production of VanX for hydrolysis of D-alanyl-D-alanine.

Reynolds PE, Depardieu F, Dutka-Malen S, Arthur M, Courvalin P.

Mol Microbiol. 1994 Sep;13(6):1065-70.

PMID:
7854121
35.

Contribution of VanY D,D-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors.

Arthur M, Depardieu F, Snaith HA, Reynolds PE, Courvalin P.

Antimicrob Agents Chemother. 1994 Sep;38(9):1899-903.

Supplemental Content

Loading ...
Support Center